2021/2022 Global Leukemia Patient Experience Survey

In 2021/2022 the CLL Advocates Network (CLLAN) in partnership with the Acute Leukemia Advocates Network (ALAN) and the CML Advocates Network (CMLAN) ran a Global Leukemia Patient Experience Survey to create a global picture of the key issues, experiences and unmet needs of leukaemia patients. This multi-country survey collected key data on important areas of patient experience such as diagnosis, treatment, patient preferences, quality of life and also impact of the COVID-19 pandemic on patient experience and outcomes. It targeted adult patients with leukemia and was made available in 10 languages. This was an international patient group-led initiative.


  • To identify priority topics, assess areas of change including (but not limited to) COVID.
  • To understand the issues and gather information on the current and emerging treatment landscape, experiences and quality of life (QoL)
  • To create further evidence about patient experience and quality of life at different points in the leukemia patient journey.
  • To aid patient advocates and advocacy groups to inform and influence stakeholder communities, industry, and policy makers – enabling evidence-based advocacy.
  • To help to identify and communicate the varying levels of information, care and support available to patients.



Developed by a panel of expert leukemia patient advocates, the questionnaire was tested twice and comprises sixteen sections with the aim to collect insight and understanding into the patient’s experience, rather than the clinical perspective. The questionnaire consisted of 200 questions (some with subquestions) including HM-PRO, a validated QoL assessment tool in those with hematological malignancies. Patients completed the sections relevant to their type of leukemia. Data on
relevant patient characteristics, such as gender, age, and countries of residence, were collected in the demographic section. The administration of the questionnaire was web-based, between 18 September 2021 and 07 January 2022 and was made available in 10 languages. It was promoted by ALAN, CLLAN, CMLAN and member organizations via websites, newsletters, emails, and social media channels. Participation was on a voluntary basis therefore may not reflect the perspectives of all leukemia patients.


There were 2646 respondents with different types of leukemia: acute myeloid leukemia (n=312), acute lymphoblastic leukemia (n=104), chronic lymphocytic leukemia (n=1202), chronic myeloid leukemia (n=896) and other types of leukemia


We are in the process of analyzing the data and expect to be having the following reports and recommendations ready by early 2023:



Link to the ASH 2022 abstract of this survey: https://ash.confex.com/ash/2022/webprogram/Paper163309.html

ASH 2022 poster:

Click here to access the poster in .pdf

Thanks to patients worldwide who took the time to complete this survey and – by that – helped us greatly in identifying areas within the patient journey where opportunities exist to improve patient care and experiences.



We’d like to thank ALAN for taking the lead in delivery of this project and the sponsors that have supported this important work.